Tevogen Bio Holdings Inc. TVGN 深 沪
等待开盘 01-14 09:30:00 美东时间
0.3138
-0.011
-3.45%
华盛通- 最 高0.3291
- 今 开0.3262
- 成交量 59.02万股
- 最 低 0.3119
- 昨 收 0.325
- 总市值 6244.62万
- 52周最高 1.92
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 0.299
- 委 比 3.56%
- 总股本 1.99亿
- 历史最高 21.09
- 量 比 0.53
- 振 幅 5.29%
- 历史最低 0.2556
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advances In-House GMP Manufacturing Capabilities
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reported significant
01-12 22:35
Tevogen Provided Updates At J.P. Morgan Healthcare Conference
Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding
01-12 22:09
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Tevogen reported significant achievements in 2025, including enhancements to its ExacTcell™ platform, expansion of its cytotoxic T lymphocyte (CTL) pipeline across viral and oncology indications, and advancements in in-house GMP cell therapy manufacturing capabilities. These milestones reflect the company's progress in scalability, pipeline breadth, and manufacturing readiness, positioning it for future clinical and commercial success. CEO Ryan S...
01-12 14:00
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
2025-11-28 17:49
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $10 to $5.
2025-11-20 21:13
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility
This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489
2025-11-06 04:22
Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings.GAAP
2025-11-04 03:55
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Bio Holdings Inc. has reaffirmed its commitment to sustainable and affordable precision medicine, focusing on accessible and scalable T cell therapies. The company highlighted progress in its ExacTcell platform with TVGN 489, addressing Long COVID and other conditions, and shared financial projections of $9–$11 billion rNPV and $6.5 billion in revenue for liver cancer prevention. Tevogen.AI advanced its PredicTcell model with Microsoft an...
2025-10-29 16:35
Tevogen Intends To Collaborate With Government Initiatives, Long COVID Patient Organizations, And Major Healthcare Providers To Expedite Development Of TVGN 489; Establishes A Dedicated Communication Channel For Long COVID Updates At longCOVID@tevogen.com
Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries,
2025-10-16 03:52
